Clinical Trial Update: Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical Resection [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports ongoing Phase 1/2 evaluation of iNeo-Vac-R01, an individualized mRNA neoantigen vaccine, as adjuvant therapy for biliary mali…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Gallbladder Cancer

Drugs mentioned

• iNeo-Vac-R01 (Neoantigen-based personalized mRNA therapy)

Snippet

Sponsor: Yifan Wang | Conditions: Biliary Malignant Tumors | Phase 1, Phase 2 | Status: RECRUITING